Rapport Therapeutics, Inc. (RAPP)
(Delayed Data from NSDQ)
$14.43 USD
+0.39 (2.78%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $14.38 -0.05 (-0.35%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RAPP 14.43 +0.39(2.78%)
Will RAPP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RAPP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for RAPP
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Citizens JMP
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
RAPP: JMP Securities Reiterates Market Outperform Rating with $28 Target | RAPP Stock News
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call